The company focuses on developing its own portfolio of plasma-derived therapeutics products, including IVIG and Albumin, using its innovative PlasmaCap EBA technology, which allows for improved efficiencies and precision in the extraction of plasma proteins. Evolve Biologics aims to bring critical therapeutics to those in need and believes that its technology will help deliver proteins at improved levels of quality and purity compared to conventional methods, ultimately improving people's lives.